A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Issue 8 (28th April 2014)

• Record Type: Journal Article
• Authors: Welch, John S.; Niu, Haixia; Uy, Geoffrey L.; Westervelt, Peter; Abboud, Camille N.; Vij, Ravi; Stockerl‐Goldstein, Keith E.; Jacoby, Meagan; Pusic, Iskra; Schroeder, Mark A.; Dipersio, John F.; Cashen, Amanda F.
• Is Part Of: American journal of hematology. Volume 89:Issue 8(2014:Aug.)
• Page Start: E103
• Page End: E108
• Publication Date: 2014-04-28
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.23735
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The response rate of non‐M3 acute myeloid leukemia (AML) to all trans retinoic acid has been limited. Using Affymetrix expression arrays, we found that in diverse AML blasts <italic>RXRA</italic> was expressed at higher levels than <italic>RARA</italic> and that mouse <italic>Ctsg‐PML‐RARA</italic> leukemia responded to bexarotene, a ligand for RXRA. We therefore performed a phase I study of combination bexarotene and decitabine in elderly and relapsed AML patients. We found that this combination was well tolerated, although outcomes were modest (1 CRi, and 3 PR among 19 patients). Correlative studies found that patients with clinical response had increased differentiation to bexarotene both <italic>in vivo</italic> and <italic>ex vivo, </italic> suggesting that pre‐treatment analysis might identify a more susceptible subgroup of patients. Am. J. Hematol. 89:E103–E108, 2014. © 2014 Wiley Periodicals, Inc.</p> </abstract>